Supplementary Figure 4: HER2 kinase domain mutants confer resistance to anti-estrogen agents in MCF7 cells. | Nature Genetics

Supplementary Figure 4: HER2 kinase domain mutants confer resistance to anti-estrogen agents in MCF7 cells.

From: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies

Supplementary Figure 4: HER2 kinase domain mutants confer resistance to anti-estrogen agents in MCF7 cells.

MCF7 HER2-mutant and control cells were compared on the basis of sensitivity to estrogen deprivation and the anti-ER agents tamoxifen and fulvestrant. a, MCF7 cells expressing the indicated HER2 mutants were serum starved for 2 d, followed by treatment with vehicle or 10 nM estradiol (E2) as indicated. After a week, relative viability compared to cells grown in complete medium was analyzed by CellTiter-Glo. Results shown are the mean +/− s.e.m. of three technical replicates and are representative of six independent experiments. b–d, MCF7 control or HER2-mutant cells were plated in complete medium containing several concentrations of tamoxifen (b), fulvestrant (c), or GDC-0810 (d). Viability was determined after a week and normalized to untreated wells. Results shown are the mean +/− s.e.m. of three technical replicates and are representative of six independent experiments.

Back to article page